
Hematólogo. Linfomas y Leucemia Linfocítica Crónica. #LEx
Joined August 2018
- Tweets338
- Following96
- Followers340
- Likes3.5K
What would be your choice for unfavorable early-stage stage Hodgkin's if there was no reimbursement issues? Are we ready for Nivo-AVD? @GuiperiniMD @cytohance @iHematologo @graham74GC @AstridPavlovsky @HemSandoval @ASkarbnik
10%Still ABVD x 4 + RT
11%Still ABVD x 6 (Rathl)
72%Nivo-AVD x 4/6
7%Bv-AVD + RT
90 votes • Final results#LEx25 - Puerto Varas. Gracias a todos por el entusiasmo! Nos vemos el 2026
#LEx2025
La diapositiva perfecta no exist..... Como nos sentimos con Manto R/R
Excelente presentación de @GuiperiniMD.
Illustrative presentation by @graham74GC in favo(u)r of NHL approach for NLPHL #ISHL13
1
2
522
Replying to @CarolinaMahuad
@CarolinaMahuad Simposio en #ISHL13 👏
Young fit male patiente with the novo leukemic CD5+ DLBCL. WBC 45.000
Would you give CNS prophylaxis w/HDMTX?
@JuanAlderuccio @mattwilson2287 @laura_korin @cytohance @iHematologo @DrMCanales @graham74GC @GuiperiniMD @tobyeyre82 @CwynKate
61%Yes, despite the evidence
39%No, because of evidence
56 votes • Final resultsWhat's your policy regarding fibrinogen measurement and cryo transfusion in patients undergoing CAR-T (usually first 10-12 days) @ASkarbnik @AnnaSureda5 @DrMCanales @Eddie_Cliff @@gloria_iacoboni @pebarba
54%Don't check it routinely
8%Check often/cryo if <150
38%Check often/cryo if <100
13 votes • Final resultsLas estratifaciones se riesgo del TRIANGLE son accesibles para LATAM!
- MIPI
- Ki67
- expresión p53 x IHQ
Algunas imágenes interesantes del suplementario
After the Matching-adjusted indirect comparison between LYMA-101 (obin) & LYMA (ritux), should we move to obinutuzumab as the anticd20 of choice in "asct eligble" MCL?
@cytohance
@iHematologo @laura_korin
@GuiperiniMD @ASkarbnik @tobyeyre82 @DrMCanales
ashpublications.org/blood/ar…
32%Yes
68%No
59 votes • Final resultsAnalisis de 10 años de Hodgkin en UC 🇨🇱 , énfasis en PET CT diagnóstico e interino. A mejorar guía GES!
@EmeVergara @hemotrasplantuc
@mjosegarciargz @PatricioRojasR
@vsandoval990 James Campbell y Mauricio Ocqueteau
revistamedicadechile.cl/ojs/…
Would you still consider CNS prophylaxis in Primary testicular DLBCL (IELSG30)?
@laura_korin @cytohance @iHematologo @mattwilson2287 @CarolinaMahuad @VictoriaIrigoin @DrMCanales @BeatrizWills
64%Yes! IV HDMTX + IT
26%Yes! But only IT
10%Not anymore
120 votes • Final resultsOld fashioned & uncomfortable question.
In DBLCL, do you think Rituximab still adds something to ICE/DHAP/GEMOX in 2d/3rd line in patients with 1º refractory to R-CHOP? It is safe, but no that cheap.
@graham74GC @AaronGoodman33 @cytohance @iHematologo @GuiperiniMD @timfenske
26%Of course
20%Don't think so
54%We will never know
89 votes • Final results 6
10
4,098
No se lo pierdan!
¡Y vamos con todo!
Ya están abiertas las inscripciones para #LEx2023 en Viña del Mar 🇨🇱
- hot topics en linfoma
- debates
- trabajos libres
- conexiones LATAM
- grandes expositores
Ingresa a cytohance-k9igex.mailerpage.…
O a través de (lymphomaexperience.cl)
Which is your preferred route of administration of Rituximab in DLBCL after C1?
@graham74GC @GuiperiniMD @AaronGoodman33 @cytohance @DrRaulCordoba @Eddie_Cliff @chanyooncheah @mattwilson2287 @iHematologo @AstridPavlovsky @laura_korin
51%Subcutaneous
49%Intravenous
188 votes • Final results60y man no comorbidites, CLL IGVH unmut, del17p+
170.000 lymphocytes. LDH 320. No richter. Treatment needed. VEN-O (First line) was chosen.
Is there any therapy to diminish the risk of infussional reaction and TLS?
@tobyeyre82 @GuiperiniMD @cytohance @Othman_Al_Sawaf @anthonymat
Resultados demográficos, citogenéticos y terapéuticos de 114 pacientes con Leucemia Mieloide Aguda no promielocítica en nuestro centro
@hemotrasplantuc @vsandoval990 @mjosegarciargz, Rojas, Ocqueteau, Campbell, Bertín, Risueño, Rodriguez, Galleguillos
scielo.cl/scielo.php?scr…
Interesantes resultados de la encuesta!
Selección abstracts #ASH22
L.Folicular-Baja carga tumoral
Estudio Fase 3
-👥️️133 observación vs 42 Rituxi x4 vs 67 R inducción+2a mantención.
-tiempo a nuevo tto: 2,7a vs 9,9a vs no alcanzado
-SG=
-Transformación: 18,2 vs 10,7 vs 13,5%
🔘¿Qué harás tú?
ash.confex.com/ash/2022/webp…
33%Observación
50%Rituximab semanal x 4
17%Rituximab + mantención
18 votes • Final resultsWhat should be the 2L in a 30y old female patient with refractory mediastinal grey zone lymphoma (RCHOP was given in 1L)?
2 polls, please comment🙏
@graham74GC
@GuiperiniMD @cytohance @AstridPavlovsky @tobyeyre82 @chanyooncheah @timfenske @DrAEvens
58%RICE/RGDP +/- RT
31%BV-Nivo +/- RT
11%Other
236 votes • Final resultsReplying to @Berninini
@Berninini can you help me with some advice on antifungal prophylaxis during Inotuzumab for ALL? There is a recommendation against azoles because of the risk of VOD
1
1






















